Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NBG 030
- Development stage
- Preclinical
- Lead developer
- NB Health Laboratory
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Parenteral
01
Overview
NBG 030 is a monoclonal antibody developed by NB Health Laboratory (NBHL) that targets the frizzled receptor. It is being investigated as an antifibrotic and antineoplastic agent, with potential applications in the treatment of fibrosis and cancer. The drug acts as a frizzled receptor antagonist, interfering with Wnt signaling pathways implicated in fibrotic diseases and tumorigenesis. As of August 2023, it remains in early research stages for both indications[1].
02
Targets
FZD (Frizzled receptor family)
Beyond the preview
Go deeper on NBG 030.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NBG 030.